Yifan Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Yifan Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Yifan Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Yifan Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Yifan Pharmaceutical Co Ltd (Yifan) develops, manufactures, and markets active pharmaceutical ingredients (API), medical products and polymer materials. The company offers a diverse healthcare portfolio that features advanced biological drugs like Ryzneuta for chemotherapy-induced neutropenia, specialized chemical injections for critical oncology, neurology, and intensive care, and innovative, government-negotiated traditional Chinese medicines (TCMs) like Compound Realgar Natural Indigo Tablets. The company also provides D-Calcium pantothenate and panthenol, PVB resin and films, and, bio-engineered cosmetic raw materials. Its pipeline products are targeted for the treatment of neutropenia, alcoholic hepatitis, acute pancreatitis, solid tumors, B-cell leukaemia, and others. Yifan is headquartered in Hangzhou, Zhejiang, China.
Headquarters
China
Address
No. 50, Qinshan, Jincheng Street, Linan City, Hangzhou, Zhejiang, 311300
Website
www.yifanyy.com
Telephone
86 400 1802019
No of Employees
4,182
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
002019 (SHE)
Revenue (2024)
$714.2M
-0.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
4.2%
(2024 vs 2023)
Market Cap*
$1.7B
Net Profit Margin (2024)
XYZ
4.7%
(2024 vs 2023)
* As of and is in US$
Yifan Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Medicines: | Ryzneuta |
| Ryzneuta (Efbemalenograstim alfa Injection) | Alkeran |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In September, Yiyi Biotechnology secured approval from the U.S. Food and Drug Administration to expand a domestic manufacturing location for Ryzneuta in China (BLA 761134/S-007). |
| 2026 | Regulatory Approval | In September, the company secured distribution rights for Boryung’s Taxotere (docetaxel injection) in China to lead its marketing, distribution, and commercialization nationwide. |
| 2026 | New Product Approvals | In May, the company was granted approval by the National Medical Products Administration for the biosimilar teriparatide injection. |
Competitor Comparison
| Key Parameters | Yifan Pharmaceutical Co Ltd | China National Accord Medicines Corporation Ltd | Sino Biopharmaceutical Ltd | CSPC Pharmaceutical Group Ltd | Hubei Guangji Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | Hong Kong | China | China |
| City | Hangzhou | Shenzhen | Hong Kong City | Shijiazhuang | Huanggang |
| State/Province | Zhejiang | Guangdong | - | Hebei | Hubei |
| No. of Employees | 4,182 | 28,336 | 22,838 | 18,626 | 1,164 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Cheng Xianfeng | President; Chairman | Executive Board | 2014 | 58 |
| Yuhong Geng | Chief Executive Officer | Senior Management | 2025 | 55 |
| Wang Feng | Chief Executive Officer | Senior Management | 2025 | 53 |
| Qian Liping | Chief Executive Officer | Senior Management | 2025 | 43 |
| Zhang Dawei | Vice President; Chief Financial Officer | Senior Management | 2025 | 45 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer